• Home
  • Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma.

Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma.

Author List
Tai W, Doolittle GC, Shah Z, Atkinson JB, Russell E, Genton RE, Moslehi JJ, Porter CB
Publication
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Publication ID (Profile URL)
https://researcherprofiles.org/profile/366103677
Publication Year
2022
PubMed ID
36220718
Publication Title
Tai W, Doolittle GC, Shah Z, Atkinson JB, Russell E, Genton RE, Moslehi JJ, Porter CB. Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma. J Heart Lung Transplant. 2022 12; 41(12):1860-1864.